To obtain credit, study the material and complete the CME Posttest and Evaluation as instructed at the end of each activity.
After completing each of these educational activities, you should be able to achieve the objective given in the activity.
Mixed states in bipolar disorder often present a clinical crisis because they can combine the most serious symptoms of both mania and depression. Mixed episodes last longer than pure manic or depressive episodes and more frequently include psychosis, substance abuse, and suicidality. The proper recognition of mixed states is crucial so that appropriate treatment that is effective and that does not worsen the course of illness can be implemented. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on mixed states in bipolar disorder. There are no prerequisites for participating in this activity.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates each of these educational activities for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest (i.e., any proprietary entity producing health care goods or services consumed by, or used on, patients) occurring within the 12 months prior to joining this activity (April 2007). The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows:
Dr. McElroy is a consultant to or member of the scientific advisory boards of Abbott, Eli Lilly, Janssen, Novartis, Ortho-McNeil, and Wyeth; is a principal or co-investigator on research studies sponsored by Abbott, American Diabetes Association, AstraZeneca, Bristol-Myers Squibb, Esai, Eli Lilly, Forest, GlaxoSmithKline, Janssen, National Institute of Mental Health, Ortho-McNeil, Pfizer, Sanofi-Synthelabo, Somaxon, and Stanley Medical Research Institute; and is inventor on U.S. Patent No. 6,323,236B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, OH, receives payments from Johnson & Johnson, which has exclusive rights under the patent. [article list]
Dr. Frye is a consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Neurocrine Biosciences, Otsuka, and Pfizer; has received grants from Abbott, Cephalon, GlaxoSmithKline, Janssen, and Pfizer; and is a member of the speakers’ bureaus for AstraZeneca, Bristol-Myers Squibb, and Otsuka. [article list]
Dr. Goldberg is a consultant for Eli Lilly, Cephalon, and GlaxoSmithKline and is a member of the speakers/advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Pfizer. [article list]
Dr. McIntyre is a consultant and member of the speakers boards for AstraZeneca, Eli Lilly, Janssen-Ortho, Organon, Wyeth, Lundbeck, GlaxoSmithKline, Oryx, Biovail, Pfizer, Prestwick, Bristol-Myers Squibb, and Shire; and has received research funding from Wyeth, GlaxoSmithKline, Merck, Servier, and AstraZeneca. [article list]
In these Brief Reports, investigational information about pharmaceutical agents may be presented that is outside U.S. Food and Drug Administration-approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. Please consult the paragraph titled “Disclosure of Off-Label Usage” at the end of each Brief Report for a complete listing of off-label or investigational uses. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
These activities have undergone a 3-tier review process: (1) the entire faculty of the series discussed the content at a peer-review planning session; (2) the Chair reviewed the activities for accuracy and fair balance; and (3) a member of the External CME Advisory Board reviewed the activities to determine whether the material is evidence-based and objective.
These Brief Reports are developed from the planning teleconference series "Treatment Strategies for Mixed Episodes in Bipolar Disorder," which was held in May and June 2007, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Eli Lilly and Company. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
 |
|
| Chair Susan L. McElroy, MD | |
| Project Assistants | Anna Esquivel, MA Julie L. Hoffman, MFA Aaron Worcester, BA |
| Project Manager | Kathryn Maceri, BA |
| Electronic Media Manager | F. Grant Whittle, PhD |
| Managing Director | Jane B. Eckstein, MA |
| Associate CME Director | Jennifer G. Alessi, MA |
| Assistant CME Director | Susan K. Beaton, BS |
| CME Editor | Becky Brown Derych, MA |
| CME Coordinator | Diane Brunner |
| External CME Advisory Board | |
Chair Michael H. Ebert, MD Vice Chair Richard C. Shelton, MD |
|
E. Sherwood Brown, PhD, MD Stephanie Cavanaugh, MD Lawrence J. Cohen, PharmD Larry Culpepper, MD, MPH John M. Downs, MD Alan J. Gelenberg, MD |
Paul King, MD Joseph A. Lieberman, III, MD Elizabeth H. B. Lin, MD Frank W. Ling, MD J. Sloan Manning, MD Meir Steiner, MD, PhD |
© 2007 Physicians Postgraduate Press, Inc. |
|
Psychiatrist.com Home
Keyword Search